Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia

Blood Cancer Journal
Miriam MarquisJosée Hébert

Abstract

Since the publication of the original article the authors noticed the the affiliation details for Paresh Vyas are incorrect. The correct affiliation details for this author are given below.

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

JAMA : the Journal of the American Medical Association
JAMA Otolaryngology-- Head & Neck Surgery
JAMA : the Journal of the American Medical Association
© 2022 Meta ULC. All rights reserved